Brainstorm Cell Therapeutics Inc. (BCLI)

NASDAQ: BCLI · Real-Time Price · USD

1.190

-0.070 (-5.56%)

At close: Apr 1, 2025, 4:00 PM

1.260

+0.070 (5.88%)

After-hours: Apr 1, 2025, 4:54 PM EDT

BCLI Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Selling, General & Admin	7.04	10.69	10.87	9.3	9.36	Upgrade
Research & Development	4.65	10.75	13.96	15.24	22.33	Upgrade
Operating Expenses	11.69	21.44	24.82	24.54	31.68	Upgrade
Operating Income	-11.69	-21.44	-24.82	-24.54	-31.68	Upgrade
Interest Expense	-0.08	-0.28	-	-	-0.13	Upgrade
Interest & Investment Income	-	-	0.55	0.08	-	Upgrade
Other Non Operating Income (Expenses)	0.15	4.53	-	-	-	Upgrade
Pretax Income	-11.62	-17.19	-24.28	-24.46	-31.81	Upgrade
Net Income	-11.62	-17.19	-24.28	-24.46	-31.81	Upgrade
Net Income to Common	-11.62	-17.19	-24.28	-24.46	-31.81	Upgrade
Shares Outstanding (Basic)	5	3	2	2	2	Upgrade
Shares Outstanding (Diluted)	5	3	2	2	2	Upgrade
Shares Change (YoY)	74.87%	17.99%	0.91%	21.22%	36.25%	Upgrade
EPS (Basic)	-2.31	-5.99	-9.97	-10.14	-15.99	Upgrade
EPS (Diluted)	-2.31	-6.00	-9.97	-10.20	-15.99	Upgrade
Free Cash Flow	-	-20.48	-19.35	-26.6	-35.57	Upgrade
Free Cash Flow Per Share	-	-7.13	-7.95	-11.03	-17.88	Upgrade
EBITDA	-11.44	-21.17	-24.54	-24.28	-31.47	Upgrade
D&A For EBITDA	0.25	0.27	0.29	0.26	0.22	Upgrade
EBIT	-11.69	-21.44	-24.82	-24.54	-31.68	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q